WIRE — Dr Reddys Laboratories shares dropped over 4% after a batch of semaglutide was found out of specification due to an active pharmaceutical ingredient issue.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.